Quantcast

Posts related to ‘Drug companies’

Diabetes Drug Approved For Europe (AMLN, LLY)

Posted: March 23, 2012 at 8:49 am

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly & Co. (NYSE: LLY) are in the news on the diabetes front.  The companies have announced that the European Commission has now ...
Read Full Story »

Durata Therapeutics Files For IPO (DRTX)

Posted: March 22, 2012 at 3:59 pm

A company called Durata Therapeutics, Inc. has filed to come public via an initial public offering.  While no terms have been set, the paperwork filed at the Securities and Exchange Commission ...
Read Full Story »

Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)

Posted: March 21, 2012 at 12:46 pm

Dendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the ...
Read Full Story »

Teva Tries NASDAQ & NYSE Exchange Hat Trick (TEVA)

Posted: March 21, 2012 at 9:47 am

This is obnoxious when companies do this.  Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is trying the hat trick where it changes exchange listings.  Now the company plans to transfer the ...
Read Full Story »

Targacept Slammed on Failed Drug Trial (TRGT, AZN)

Posted: March 20, 2012 at 12:44 pm

Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214 following a ...
Read Full Story »

The Generic Boniva Opportunity (RHHBY, MYL)

Posted: March 19, 2012 at 4:02 pm

The Food and Drug Administration approval of the first generic versions of osteoporosis drug Boniva won't be the end of Roche Holding AG (OTC: RHHBY) for its marketing of Boniva in the ...
Read Full Story »

Biopharma Firm Crushed by Merck Deal Cancellation (CRME, MRK)

Posted: March 19, 2012 at 11:11 am

Canadian-based drug company Cardiome Pharma Corp. (NASDAQ: CRME) announced this morning that Merck & Co. Inc. (NYSE: MRK) has cancelled further development of an oral version of a Cardiome drug ...
Read Full Story »

Ampio Shares Booming on Positive Test Results (AMPE)

Posted: March 19, 2012 at 10:45 am

Drug maker Ampio Pharmaceuticals Inc. (NASDAQ: AMPE) reported this morning that clinical trials of the company’s Optina treatment for a type of macular disease have been successful: A preliminary assessment, ...
Read Full Story »

Discovery Labs Shareholders Get Smacked on Secondary Offering (DSCO)

Posted: March 16, 2012 at 3:03 pm

Respiratory drug maker Discovery Laboratories Inc. (NASDAQ: DSCO) priced a secondary offering of slightly more than 16 million shares this morning, and the stock is getting pummeled as a result. ...
Read Full Story »

OncoGenex Prices Secondary Offering, Shares Fall (OGXI)

Posted: March 16, 2012 at 12:47 pm

Cancer therapy developer OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI) has priced a secondary offering of 4.165 million common shares at $12.00/share, a discount of 31% to yesterday’s closing price of $17.43. ...
Read Full Story »

Another Boost For Threshold (THLD)

Posted: March 16, 2012 at 7:59 am

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) has been one of the top performing stocks of 2012.  Not just in emerging pharma and in biotech, but across the board.  Now we have ...
Read Full Story »

VIVUS Scores FDA Backing For Qnexa Against Obesity (VVUS, OREX, ARNA)

Posted: February 22, 2012 at 4:36 pm

VIVUS, Inc. (NASDAQ: VVUS) is going to likely have a huge day on Thursday.  The FDA panel reviewing its Qnexa drug to treat obesity has voted overwhelmingly to offer FDA panel backing ...
Read Full Story »

Crushing Blow for Gilead, Billions of Dollars (GILD)

Posted: February 17, 2012 at 7:22 am

Gilead Sciences Inc. (NASDAQ: GILD) is being crushed after a disappointing result in its Hepatitis C treatment after reporting that a majority of hepatitis C genotype-1 patients who had a ...
Read Full Story »

Merck Close to 52-Week High After Earnings (MRK)

Posted: February 2, 2012 at 8:55 am

Merck & Company, Inc. (NYSE: MRK) is trading up after its earnings report.  With a high dividend yield of 4.4%, many investors are watching this despite a stance of little ...
Read Full Story »

Pfizer Sneaks By Earnings Estimates (PFE, MRK)

Posted: January 31, 2012 at 7:17 am

Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company's guidance may be getting in the way a bit.  The ...
Read Full Story »